Summary
Amgen Inc. reported strong financial results for the fiscal year ended December 31, 2009, demonstrating resilience despite a challenging market environment. The company's primary products, including Aranesp®, EPOGEN®, Neulasta®, NEUPOGEN®, and Enbrel®, continued to drive significant revenue, although Aranesp® sales experienced a notable decline, primarily attributed to updated product labeling related to safety concerns. Despite this, Amgen maintained a robust balance sheet with substantial cash, cash equivalents, and marketable securities, indicating financial strength and flexibility. The company is actively managing its product pipeline, with significant developments expected from its late-stage product candidate, denosumab, which is under regulatory review and has shown promising clinical trial results. Amgen is also navigating a complex regulatory and reimbursement landscape, particularly concerning its erythropoiesis-stimulating agent (ESA) products, which are subject to ongoing scrutiny and potential label changes. Looking ahead, Amgen faces ongoing challenges related to evolving healthcare reforms, increased competition, and regulatory pressures. However, the company's strategic focus on innovation, coupled with its strong financial position, positions it to continue its mission of delivering innovative therapies to patients facing grievous illnesses.
Financial Highlights
52 data points| Revenue | $14.64B |
| SG&A Expenses | $3.82B |
| Operating Expenses | $9.14B |
| Operating Income | $5.51B |
| Interest Expense | $578.00M |
| Net Income | $4.61B |
| EPS (Basic) | $4.53 |
| EPS (Diluted) | $4.51 |
| Shares Outstanding (Basic) | 1.02B |
| Shares Outstanding (Diluted) | 1.02B |
Key Highlights
- 1Aranesp® sales declined by 15% year-over-year to $2.65 billion, primarily due to safety-related label changes and increased regulatory scrutiny, particularly impacting its use in supportive cancer care.
- 2EPOGEN® sales saw a 5% increase to $2.57 billion, driven by patient population growth, increased dose utilization, and a higher average net sales price.
- 3Neulasta®/NEUPOGEN® sales remained relatively flat at $4.64 billion, with a slight increase in U.S. sales offset by a decrease in international sales, largely due to foreign currency exchange rate impacts.
- 4Enbrel® sales decreased by 3% to $3.49 billion, influenced by an unfavorable change in wholesaler inventories and increased competitive activity, although it maintained a leading position in rheumatology and dermatology.
- 5Denosumab, a key late-stage product candidate, demonstrated positive Phase 3 trial results for bone metastases and received a positive opinion from the European Medicines Agency (EMA) for osteoporosis treatment, with a PDUFA action date set for July 25, 2010, for its U.S. submission.
- 6The company's R&D expenses decreased by 5% to $2.86 billion, reflecting the completion of certain late-stage clinical studies for denosumab and Vectibix®.
- 7Amgen ended the year with $13.4 billion in cash, cash equivalents, and marketable securities, underscoring its strong financial health and ability to fund operations and strategic initiatives.